Potential confli...

Background. A herpes simplex virus (HSV)–2 candidate vaccine consisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital herpes disease in HSV-1–seronegative women but not in men or HSV-1–seropositive women. Methods. To determine the effect of HSV-1 serostatus on effectiveness of different vaccines, we tested gD2 in alum/MPL, gD2 in Freund’s adjuvant, and dl5–29 (a replication-defective HSV-2 mutant) in HSV-1–seropositive or HSV-1–seronegative guinea pigs. Results. In HSV-1–seronegative animals, dl5–29 induced the highest titers of neutralizing antibody, and after vaginal challenge with wild-type virus, dl5–29 resulted in lower rates of vaginal shedding, lower levels of HSV DNA in ganglia, and a trend for less acute and recurrent genital herpes, compared with the gD2 vaccines. In HSV-1–seropositive animals, all 3 vaccines induced similar titers of neutralizing antibodies and showed similar levels of protection against acute and recurrent genital herpes after vaginal challenge with wild-type virus, but dl5–29 reduced vaginal shedding after challenge more than did the gD2 vaccines. Conclusions. dl5–29 Is an effective vaccine in both HSV-1–seropositive and HSV-1–seronegative guinea pigs and was superior to gD2 vaccines in reducing virus shedding after challenge in both groups of animals. dl5–29 Might reduce transmission of HSV-2